Posted from: Friday, July 06, 2018 - 04:33 PM - Present

Avastin Receives New Indication

June 13, 2018 – The U.S. FDA has approved a new indication for Avastin® (bevacizumab), manufactured by Genentech. The drug is now approved for use in combination with chemotherapy (carboplatin and paclitaxel), and then as a single agent following chemotherapy, to treat women who have advanced (stage III or IV) ovarian cancer and who have undergone initial surgical resection.

Approximately 80% of ovarian cancer is identified only after it has reached an advanced stage. A monoclonal antibody, Avastin helps to inhibit tumor growth by blocking a specific protein. Median progression free survival with Avastin in a clinical study of women with ovarian cancer was 18.2 months. With chemotherapy alone, the median progression free survival time was 12 months.

Avastin carries a black box warning cautioning that its use is associated with gastrointestinal perforation, surgery and wound healing complications, and severe or fatal hemorrhage. The product holds ten U.S. FDA approved indications across six different types of cancer, and was first approved for use in the United States in 2004.

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by U.S. mail or by fax.

Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.


Last Updated Thursday, September 19, 2019 - 05:14 PM.